Dr. Jhaveri on Results of Taselisib in PIK3CA-Mutated Metastatic Solid Tumors OncLive 1:25 6 years ago 415 Далее Скачать
Dr. Jhaveri Discusses a Basket Trial of Taselisib in Solid Tumors OncLive 1:53 6 years ago 116 Далее Скачать
Dr. Hurvitz on Patient Outcomes and PIK3CA Mutations Targeted Oncology 1:59 10 years ago 1 220 Далее Скачать
BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR+/HER2-... ecancer 3:53 5 years ago 2 299 Далее Скачать
Dr. Jhaveri on Acquired Resistance to CDK 4/6 Inhibitors in Breast Cancer OncLive 1:13 6 years ago 544 Далее Скачать
Dr. Tolaney on Presence of PIK3CA and ESR1 Mutations in MONARCH 2 Trial in Breast Cancer OncLive 1:58 5 years ago 1 645 Далее Скачать
Dr. Jhaveri on the Use of Trastuzumab Biosimilars in Breast Cancer OncLive 0:51 5 years ago 530 Далее Скачать
ASCO: Alpelisib Plus Fulvestrant for PIK3CA-Mutated Breast Cancer After Failure of CDK4/6 Inhibitors PracticeUpdate 7:49 4 years ago 1 324 Далее Скачать
Taselisib with fulvestrant slows growth of advanced breast cancer ecancer 7:33 6 years ago 176 Далее Скачать
Dr. Jhaveri Discusses Potential Targets of Inflammatory Breast Cancer Targeted Oncology 3:02 11 years ago 1 082 Далее Скачать
Treatment Following Relapse on CDK4/6 Inhibitors Targeted Oncology 4:39 5 years ago 127 Далее Скачать
BYLieve Study Cohort A: alpelisib + ET in PIK3CA-mutant, HR+, HER2-, advanced breast cancer VJOncology 3:07 2 years ago 828 Далее Скачать
Why Do Cancers Have PIK3CA Mutations and How Can They Be Targeted for Cancer Treatment? Medical-Question 3:06 1 year ago 688 Далее Скачать
Liquid Biopsy Analysis of FGFR3 and PIK3CA for Disease Surveillance in Bladder Cancer Targeted Oncology 1:40 7 years ago 227 Далее Скачать
PIKing The Right Strategy for patients with HR+/HER2-, PIK3CA mutation Cancer education made simple # Chandrakanth MV 16:08 4 years ago 244 Далее Скачать
